^
Association details:
| Biomarker: | MFSD2A overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
Published date:
08/04/2023
Excerpt:
Higher expression of MFSD2A in tumor tissues of AGC patients was associated with better response to anti-PD-1 immunotherapy...The overexpression of MFSD2A in GC cells enhanced the efficacy of anti-PD-1 immunotherapy in vivo by reprogramming the tumor microenvironment (TME)...MFSD2A potentially serves as a predictive biomarker for anti-PD-1 immunotherapy response in AGC patients.
DOI:
10.1002/cac2.12476